“Mendonyl™ is an extraordinary reflection of the pharmaceutical
and nutritional industry’s need for advancement
in developing an economical and quality Povidone and Crospovidone.”
Mendonyl™
“Mendonyl™ is an extraordinary reflection of the pharmaceutical
and nutritional industry’s need for advancement
in developing an economical and quality Povidone and Crospovidone.”
Mendonyl™
The Pharmaceutical Formulator’s Choice Tablet Binder and Disintegrate
Povidone – Crospovidone
MENDONYL™ Povidone
Comparative binder efficiency modeling of dry granulation binders using roller compaction.
0 CommentsDrug Dev Ind Pharm. 2017 Apr;43(4):574-583. doi: 10.1080/03639045.2016.1272118. Epub 2017 Jan 5. Gupte A1, DeHart M1, Stagner WC2, Haware RV2. Author information 1 a…
Read MorePharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies.
0 CommentsDrug Dev Ind Pharm. 2017 Apr;43(4):584-594. doi: 10.1080/03639045.2016.1274901. Epub 2017 Jan 8. Sawicki E1, Schellens JH2,3, Beijnen JH1,2,3, Nuijen B1. Author information 1 a…
Read MoreA minitablet formulation made from electrospun nanofibers.
0 CommentsEur J Pharm Biopharm. 2017 May;114:213-220. doi: 10.1016/j.ejpb.2017.01.022. Epub 2017 Feb 4. Poller B1, Strachan C2, Broadbent R3, Walker GF4. Author information 1 School…
Read MoreOral bioavailability enhancement of flubendazole by developing nanofibrous solid dosage forms.
0 CommentsDrug Dev Ind Pharm. 2017 Jul;43(7):1126-1133. doi: 10.1080/03639045.2017.1298121. Epub 2017 Mar 8. Vigh T1, Démuth B1, Balogh A1, Galata DL1, Van Assche I2, Mackie C2, Vialpando M2, Van…
Read More[Application of synthetic and semisynthetic polymers (Kollidon K30 and hydroxypropylmethylcellulose) as carriers of ketoprofen in solid oral prolonged-release dosage forms].
0 CommentsPolim Med. 2016 Jul-Dec;46(2):145-153. doi: 10.17219/pim/69296. [Article in Polish] Linka W1, Kot M1, Kołodziejczyk M1. Author information 1 Zakład Technologii Postaci Leku, Uniwersytet…
Read MoreNew gentle-wing high-shear granulator: impact of processing variables on granules and tabletscharacteristics of high-drug loading formulation using design of experiment approach.
0 CommentsDrug Dev Ind Pharm. 2017 Oct;43(10):1584-1600. doi: 10.1080/03639045.2017.1326930. Epub 2017 May 19. Fayed MH1, Abdel-Rahman SI2, Alanazi FK3, Ahmed MO2, Tawfeek HM2, Al-Shdefat RI1. Author information…
Read MoreFormulation and Dissolution enhancement of Meloxicam tablets using Polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer and Povidone in combination.
0 CommentsPak J Pharm Sci. 2017 Mar;30(2):407-414. Noor R1, Hasan SMF1, Hassan F1, Rehman A2. Author information 1 Department of Pharmaceutics, Faculty of Pharmacy and…
Read MoreInfluence of polyvinylpyrrolidone, microcrystalline cellulose and colloidal silicon dioxide on technological characteristics of a high-dose Petiveria alliacea tablet.
0 CommentsDrug Dev Ind Pharm. 2017 Dec;43(12):2011-2015. doi: 10.1080/03639045.2017.1359621. Epub 2017 Aug 3. García-Pérez ME1,2, Lemus-Rodríguez Z1, Hung-Arbelo M1, Vistel-Vigo M1. Author information 1 a…
Read MoreStudy of controlled-release floating tablets of dipyridamole using the dry-coated method.
0 CommentsDrug Dev Ind Pharm. 2018 Jan;44(1):116-124. doi: 10.1080/03639045.2017.1386198. Epub 2017 Oct 17. Chen K1, Wen H1, Yang F1, Yu Y1, Gai X1, Wang H1, Li P1, Pan W1, Yang…
Read MoreDesign and Evaluation of Bilayer Pump Tablet of Flurbiprofen Solid Dispersion for Zero-Order Controlled Delivery.
0 CommentsDesign and Evaluation of Bilayer Pump Tablet of Flurbiprofen Solid Dispersion for Zero-Order Controlled Delivery. Cheng L1, Li T1, Dong L1, Wang X1, Huo Q1, Wang H1, Jiang…
Read MoreStatistical moments in modelling of swelling, erosion and drug release of hydrophilic matrix-tablets.
0 CommentsAbstract Statistical moments were evaluated as suitable parameters for describing swelling and erosion processes (along with drug release) in hydrophilic…
Read MoreDevelopment and analytical characterization of a new antiparasitic fenbendazole compound tablet and pharmacokinetic investigations after its oral administration to dogs.
0 CommentsAbstract The objective of this study was to prepare a new compound fenbendazole tablet containing 29.7 % fenbendazole, 1.50 % praziquantel and…
Read More
MENDONYL™ Crospovidone
Crospovidone and Microcrystalline Cellulose: A Novel Description of Pharmaceutical Fillers in the Gastrointestinal Tract.
0 CommentsAm J Surg Pathol. 2017 Apr;41(4):564-569. doi: 10.1097/PAS.0000000000000790. Shaddy SM1, Arnold MA, Shilo K, Frankel WL, Harzman AE, Stanich PP, Singhi AD, Yearsley MM, Arnold CA. Author information 1…
Read MoreDifference in the Dissolution Behaviors of Tablets Containing Polyvinylpolypyrrolidone (PVPP) Depending on Pharmaceutical Formulation After Storage Under High Temperature and Humid Conditions.
0 CommentsJ Pharm Pharm Sci. 2016 Oct - Dec;19(4):511-519. doi: 10.18433/J3HW3Q. Takekuma Y1, Ishizaka H, Sumi M, Sato Y, Sugawara M. Author information 1 Faculty of…
Read MoreA pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation.
0 CommentsDrug Deliv Transl Res. 2017 Jun;7(3):450-459. doi: 10.1007/s13346-017-0367-6. Moutasim MY1, ElMeshad AN2, El-Nabarawi MA2. Author information 1 Department of Pharmaceutics and Industrial Pharmacy,…
Read MoreEvaluation of disintegrants functionality for orodispersible mini tablets.
0 CommentsDrug Dev Ind Pharm. 2017 Nov;43(11):1770-1779. doi: 10.1080/03639045.2017.1339081. Epub 2017 Jun 21. Soulairol I1,2, Chaheen M1,3, Tarlier N1, Aubert A1, Bataille B1, Sharkawi T1. Author information…
Read MoreFormulation strategy towards minimizing viscosity mediated negative food effect on disintegration and dissolution of immediate release tablets.
0 CommentsFormulation strategy towards minimizing viscosity mediated negative food effect on disintegration and dissolution of immediate release tablets. Zaheer K1, Langguth P1. Author…
Read MoreDesign and Evaluation of Bilayer Pump Tablet of Flurbiprofen Solid Dispersion for Zero-Order Controlled Delivery.
0 CommentsDesign and Evaluation of Bilayer Pump Tablet of Flurbiprofen Solid Dispersion for Zero-Order Controlled Delivery. Cheng L1, Li T1, Dong L1, Wang X1, Huo Q1, Wang H1, Jiang…
Read MoreThe Impact of Amorphisation and Spheronization Techniques on the Improved in Vitro & in Vivo Performance of Glimepiride Tablets.
0 CommentsMakar RR1, Latif R2, Hosni EA3, El Gazayerly ON2. Author information Adv Pharm Bull. 2017 Dec;7(4):557-567. doi: 10.15171/apb.2017.067. Epub 2017 Dec 31. Abstract Purpose: Triple…
Read MoreDevelopment and analytical characterization of a new antiparasitic fenbendazole compound tablet and pharmacokinetic investigations after its oral administration to dogs.
0 CommentsAbstract The objective of this study was to prepare a new compound fenbendazole tablet containing 29.7 % fenbendazole, 1.50 % praziquantel and…
Read MoreMendonyl™ Povidone
K17, K25, K30, K90
SAMPLE DENSITIES
| Product name | Typical Bulk density(g/ml) | Typical tapped density(g/ml) |
| Mendonyl™ XL | 0.20-0.30 | 0.30-0.40 |
| Mendonyl™ XL-10 | 0.20-0.30 | 0.30-0.40 |
| Product name | Typical Bulk density(g/ml) | Typical tapped density(g/ml) |
| Mendonyl™ K25 | 0.40-0.50 | 0.50-0.60 |
| Mendonyl™ K30 | 0.40-0.50 | 0.50-0.60 |
Mendonyl™ Crospovidone
XL, XL-10
MICROBIOLOGICAL STATUS
| MAX 100 Aerobic Plate Count CFU/g | ||
| MAX 100 Mold and Yeast CFU/g | ||
| No Escherichia /g | ||
| No Pseudomonas aeruginosa /g | ||
| No Salmonella /10g | ||
| No Staphylococcus aureus /g |
SPECIFICATIONS AND BENCHMARK
Mendonyl™ Povidone K25
Dropdown to see how we compare.
| K25 | |||
| TEST | Mendonyl™ | Competitor A | Competitor B |
| Identification, A B C D E | Complies | Complies | Complies |
| Appearance of solution | Clear, ≤B6,BY6 or R6 | Clear, ≤B6,BY6 or R6 | Lighter than, ≤B6,BY6 or R6 |
| PH(in 5% solution) | 3-5 | 3-5 | 3-5 |
| Viscosity, as K-value | 22.5-27 | 22.5-27 | 24-26 |
| Aldehyde, ppm | ≤500 | ≤500 | ≤500 |
| Peroxides (as H2O2), ppm | ≤400 | ≤400 | ≤400 |
| Formic Acid, % | ≤0.5 | ≤0.5 | ≤0.5 |
| Hydrazine, ppm | ≤1 | ≤1 | ≤1 |
| Impurity A (VP),ppm | ≤10 | ≤10 | ≤5.0 |
| Impurity B (2-pyrrolidone ),% | ≤3.0 | ≤3.0 | ≤3.0 |
| Heavy metals, ppm | ≤10 | ≤10 | ≤10 |
| Water, % | ≤5.0 | ≤5.0 | ≤5.0 |
| Sulphated ash,% | ≤0.1 | ≤0.1 | ≤0.1 |
| Assay, as Nitrogen content,% | 11.5-12.8 | 11.5-12.8 | – |
SPECIFICATIONS AND BENCHMARK
Mendonyl™ Povidone K30
Dropdown to see how we compare.
| K30 | |||
| TEST | Mendonyl™ | Competitor A | Competitor B |
| Identification, A B C D E | Complies | Complies | Complies |
| Appearance of solution | Clear, ≤B6,BY6 or R6 | Lighter than, ≤B6,BY6 or R6 | Lighter than, ≤B6,BY6 or R6 |
| PH(in 5% solution) | 3-5 | 3-5 | 3-5 |
| Viscosity, as K-value | 27-32.4 | 27-32.4 | 29-32 |
| Aldehyde, ppm | ≤500 | ≤500 | ≤500 |
| Peroxides (as H2O2), ppm | ≤400 | ≤400 | ≤400 |
| Formic Acid, % | ≤0.5 | ≤0.5 | ≤0.5 |
| Hydrazine, ppm | ≤1 | ≤1 | ≤1 |
| Impurity A (VP),ppm | ≤10 | ≤10 | ≤5.0 |
| Impurity B (2-pyrrolidone ),% | ≤3.0 | ≤3.0 | ≤3.0 |
| Heavy metals, ppm | ≤10 | ≤10 | ≤10 |
| Water, % | ≤5.0 | ≤5.0 | ≤5.0 |
| Sulphated ash,% | ≤0.1 | ≤0.1 | ≤0.1 |
| Assay, as Nitrogen content,% | 11.5-12.8 | 12.0-12.8 | – |
SPECIFICATIONS AND BENCHMARK
Mendonyl™ Povidone K90
Dropdown to see how we compare.
| K90 | |||
| TEST | Mendonyl™ | Competitor A | Competitor B |
| Identification, A B C D E | Complies | Complies | Complies |
| Appearance of solution | Clear, ≤B6,BY6 or R6 | Lighter than, ≤B6,BY6 or R6 | Lighter than, ≤B6,BY6 or R6 |
| PH(in 5% solution) | 4-7 | 4-7 | 4-7 |
| Viscosity, as K-value | 81-97 | 81-96.3 | 85-95 |
| Aldehyde, ppm | ≤500 | ≤500 | ≤500 |
| Peroxides (as H2O2), ppm | ≤400 | ≤400 | ≤400 |
| Formic Acid, % | ≤0.5 | ≤0.5 | ≤0.5 |
| Hydrazine, ppm | ≤1 | ≤1 | ≤1 |
| Impurity A (VP),ppm | ≤10 | ≤10 | ≤10 |
| Impurity B (2-pyrrolidone ),% | ≤3.0 | ≤3.0 | ≤1 |
| Heavy metals, ppm | ≤10 | ≤10 | ≤10 |
| Water, % | ≤5.0 | ≤5.0 | ≤5.0 |
| Sulphated ash,% | ≤0.1 | ≤0.1 | ≤0.1 |
| Assay, as Nitrogen content,% | 11.5-12.8 | 12.0-12.8 | – |
SPECIFICATIONS AND BENCHMARK
Mendonyl™ Crospovidone XL
Dropdown to see how we compare.
| TEST | Mendonyl™ XL | Competitor A | Competitor B |
| Identification, A B C | Pass | Pass | Pass |
| Identification D | Type A | Type A | Type A |
| Solubility (Insoluble in ) | practically insoluble in water | ||
| PH ( in 1% suspension ) | 5.0 – 8.0 | 5.0 – 8.0 | 5.0 – 8.0 |
| Loss on drying | ≦5.0% | ≦5.0% | ≦5.0% |
| Water | ≦5.0% | ≦5.0% | ≦5.0% |
| Water-soluble matter | ≦1.0% | ≦1.0% | ≦1.0% |
| Acid-Alcohol soluble matter | ≦1.0% | ≦1.0% | ≦1.0% |
| Peroxides ( as H2O2 ) | ≦400ppm | ≦400ppm | ≦400ppm |
| Free N-vinylpyrrolidone | ≦10ppm | ≦10ppm | ≦5ppm |
| Residue on ignition | ≦0.1% | ≦0.1% | ≦0.1% |
| Heavy metals | ≦10ppm | ≦10ppm | ≦5ppm |
| Assay, as Nitrogen content | 11.0 – 12.8 | 12.0 – 12.8 | 11.0 – 12.8 |
SPECIFICATIONS AND BENCHMARK
Mendonyl™ Crospovidone XL-10
Dropdown to see how we compare.
| TEST | Mendonyl™ XL-10 | Competitor A | Competitor B |
| Identification, A B C | Pass | Pass | Pass |
| Identification D | Type A | Type A | Type A |
| Solubility (Insoluble in ) | practically insoluble in water | ||
| PH ( in 1% suspension ) | 5.0 – 8.0 | 5.0 – 8.0 | 5.0 – 8.0 |
| Loss on drying | ≦5.0% | ≦5.0% | ≦5.0% |
| Water | ≦5.0% | ≦5.0% | ≦5.0% |
| Water-soluble matter | ≦1.0% | ≦1.0% | ≦1.0% |
| Acid-Alcohol soluble matter | ≦1.0% | ≦1.0% | ≦1.0% |
| Peroxides ( as H2O2 ) | ≦400ppm | ≦400ppm | ≦400ppm |
| Free N-vinylpyrrolidone | ≦10ppm | ≦10ppm | ≦5ppm |
| Residue on ignition | ≦0.1% | ≦0.1% | ≦0.1% |
| Heavy metals | ≦10ppm | ≦10ppm | ≦5ppm |
| Assay, as Nitrogen content | 11.0 – 12.8 | 12.0 – 12.8 | 11.0 – 12.8 |